Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:28:34 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:PFE from 2023-04-27 to 2024-04-26 - 102 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 06:45U:PFENews ReleaseU.S. FDA Approves Pfizer's BEQVEZ(TM) (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
2024-04-24 16:37U:PFENews ReleasePfizer Declares Second-Quarter 2024 Dividend
2024-04-22 08:08U:PFENews ReleaseEuropean Commission Approves Pfizer's EMBLAVEO(TM) for Patients with Multidrug-Resistant Infections and Limited Treatment Options
2024-04-11 10:00U:PFENews ReleasePfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
2024-04-09 06:45U:PFENews ReleasePfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO(TM) in Adults Aged 18 to 59 at Increased Risk for RSV Disease
2024-04-08 12:44U:PFENews ReleaseALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
2024-03-20 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
2024-03-13 04:00U:PFENews ReleaseEuropean Commission Approves Pfizer's PREVENAR 20(TM) to Help Protect Infants and Children Against Pneumococcal Disease
2024-03-12 06:45U:PFENews ReleasePfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS(TM) Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2024-03-05 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-29 17:40U:PFENews ReleasePfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
2024-02-29 08:00U:PFENews ReleasePfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO(TM) for RSV in Older Adults
2024-02-26 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2024-02-19 07:45U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s VELSIPITY ‚ ® for Patients with Moderately to Severely Active Ulcerative Colitis
2024-02-15 10:00U:PFENews ReleasePfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
2024-02-15 08:45U:PFENews ReleaseGlobal Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
2024-02-14 08:30U:PFENews ReleaseAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-14 08:00U:PFENews ReleaseCarrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
2024-02-06 06:45U:PFENews ReleaseArvinas and Pfizer ¢ € ™s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
2024-02-05 10:00U:PFENews ReleaseBreaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
2024-02-02 06:45U:PFENews ReleaseTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2024-01-30 06:45U:PFENews ReleasePfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
2024-01-26 12:00U:PFENews ReleaseEuropean Medicines Agency Validates Type II Variation Application for PADCEV ‚ ® (enfortumab vedotin) with KEYTRUDA ‚ ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-01-26 12:00U:PFENews ReleaseEuropean Medicines Agency Validates Type II Variation Application for PADCEV ¢ „ ¢ (enfortumab vedotin) with KEYTRUDA ‚ ®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-01-10 16:30U:PFENews ReleasePfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2024-01-09 06:45U:PFENews ReleaseTIVDAK ‚ ® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
2024-01-09 06:45U:PFENews ReleaseTIVDAK ‚ ® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
2024-01-08 10:35U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s TALZENNA ‚ ® in Combination with XTANDI ‚ ® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
2024-01-02 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-12-19 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
2023-12-15 17:00U:PFENews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) with KEYTRUDA ‚ ® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-15 17:00U:PFENews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) with KEYTRUDA ‚ ® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-14 16:30U:PFENews ReleasePfizer Declares First-Quarter 2024 Dividend
2023-12-14 07:39U:PFENews ReleasePfizer Completes Acquisition of Seagen
2023-12-13 06:45U:PFENews ReleasePfizer Provides Full-Year 2024 Guidance
2023-12-12 06:45U:PFENews ReleasePfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
2023-12-11 16:30U:PFENews ReleaseFDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
2023-12-09 19:00U:PFENews ReleaseMarstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
2023-12-08 07:55U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s ELREXFIO ‚ ® for Relapsed and Refractory Multiple Myeloma
2023-12-05 13:34U:PFENews ReleaseArvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE ‚ ®) and Plans to Expand Vepdegestrant Development Program
2023-12-01 06:45U:PFENews ReleasePfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
2023-11-28 17:05U:PFENews ReleaseArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
2023-11-21 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-11-16 22:33U:PFENews ReleasePfizer and Astellas' XTANDI ‚ ® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
2023-11-02 10:52U:PFENews ReleasePfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
2023-11-02 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-10-31 06:45U:PFENews ReleasePfizer Reports Third-Quarter 2023 Results
2023-10-26 06:45U:PFENews ReleasePfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
2023-10-20 15:35U:PFENews ReleaseFDA Approves PENBRAYA ¢ „ ¢, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
2023-10-15 19:44U:PFENews ReleaseEverest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
2023-10-15 18:37U:PFENews ReleaseAstellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
2023-10-15 18:06U:PFENews ReleaseArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
2023-10-13 16:30U:PFENews ReleasePfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
2023-10-13 09:00U:PFENews ReleaseU.S. FDA Approves Pfizer ¢ € ™s VELSIPITY ¢ „ ¢ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
2023-10-05 16:30U:PFENews ReleasePfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
2023-10-04 16:30U:PFENews ReleasePfizer Declares Fourth-Quarter 2023 Dividend
2023-09-27 07:01U:PFENews ReleaseGinkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
2023-09-22 15:16U:PFENews ReleasePfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO ¢ „ ¢ for RSV
2023-09-19 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-09-19 02:00U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s LITFULO ¢ „ ¢ for Adolescents and Adults With Severe Alopecia Areata
2023-09-18 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
2023-09-12 19:30U:PFENews ReleaseEuropean Medicines Agency Validates Type II Variation for Astellas' XTANDI ‚ ® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
2023-09-12 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-09-11 13:50U:PFENews ReleasePfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
2023-09-05 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-08-30 10:00U:PFENews ReleasePfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
2023-08-30 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
2023-08-24 11:52U:PFENews ReleaseEuropean Commission Approves Pfizer ¢ € ™s ABRYSVO ¢ „ ¢ to Help Protect Infants through Maternal Immunization and Older Adults from RSV
2023-08-23 20:15U:PFENews ReleaseEverest Medicines Announces Interim Results for First Half of 2023
2023-08-23 06:45U:PFENews ReleaseFDA Grants Priority Review for XTANDI ‚ ® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
2023-08-21 17:31U:PFENews ReleaseU.S. FDA Approves ABRYSVO ¢ „ ¢, Pfizer ¢ € ™s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
2023-08-14 14:08U:PFENews ReleasePfizer ¢ € ™s ELREXFIO ¢ „ ¢ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
2023-08-01 06:45U:PFENews ReleasePfizer Reports Second-Quarter 2023 Results
2023-07-31 16:30U:PFENews ReleaseArvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC ‚ ® ER degrader being developed in ER+/HER2- Breast Cancer
2023-07-21 15:02U:PFENews ReleasePfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
2023-07-19 17:22U:PFENews ReleasePfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
2023-07-18 07:00U:PFENews ReleaseFlagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs
2023-07-06 09:00U:PFENews ReleaseCarrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
2023-07-06 08:00U:PFENews ReleaseCaribou Biosciences Announces $25 Million Equity Investment from Pfizer
2023-06-28 06:45U:PFENews ReleaseFDA Approves Pfizer ¢ € ™s NGENLA ¢ „ ¢, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
2023-06-27 06:45U:PFENews ReleaseFDA Accepts Pfizer ¢ € ™s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
2023-06-26 06:45U:PFENews ReleasePfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
2023-06-23 17:51U:PFENews ReleaseFDA Approves Pfizer ¢ € ™s LITFULO ¢ „ ¢ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
2023-06-22 06:45U:PFENews ReleasePfizer Declares Third-Quarter 2023 Dividend
2023-06-20 18:34U:PFENews ReleasePfizer ¢ € ™s TALZENNA ‚ ® in Combination with XTANDI ‚ ® Receives U.S. FDA Approval
2023-06-20 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
2023-06-06 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
2023-06-01 10:00U:PFENews ReleasePhase 3 Studies of Pfizer ¢ € ™s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
2023-05-31 17:49U:PFENews ReleaseU.S. FDA Approves ABRYSVO ¢ „ ¢, Pfizer ¢ € ™s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
2023-05-30 06:45U:PFENews ReleasePfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
2023-05-25 17:00U:PFENews ReleasePfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
2023-05-25 17:00U:PFENews ReleaseAstellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
2023-05-25 11:21U:PFENews ReleasePfizer ¢ € ™s PAXLOVID ¢ „ ¢ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
2023-05-18 16:59U:PFENews ReleaseFDA Advisory Committee Votes in Support of Approval for Pfizer ¢ € ™s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
2023-05-16 19:15U:PFENews ReleasePfizer Prices $31,000,000,000 Debt Offering
2023-05-16 06:00U:PFENews ReleaseIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
2023-05-15 07:52U:PFENews Release ‚  Pfizer Announces Proposed Notes Offering
2023-05-08 07:01U:PFENews ReleaseArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
2023-05-02 06:45U:PFENews ReleasePfizer Reports First-Quarter 2023 Results
2023-04-30 23:51U:PFENews ReleasePfizer data show Xtandi, leuprolide reduce death risk
2023-04-29 10:45U:PFENews ReleaseXTANDI ‚ ® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
2023-04-27 15:42U:PFENews ReleaseU.S. FDA Approves PREVNAR 20 ‚ ®, Pfizer ¢ € ™s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children